Granisetron enters antiemetic market.
D000970:Antineoplastic Agents / Q000009:adverse effects; D017829:Granisetron / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000517:prevention & control; D011358:Product Surveillance, Postmarketing; D014839:Vomiting / Q000517:prevention & control
D000970:Antineoplastic Agents; D017829:Granisetron